Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma.
Journal: Expert review of hematology
Published: May 27, 2026
The ClinicalTrials.gov Landscape of Multiple Myeloma Clinical Trials: A 20-Year Analysis of Geographic Distribution and Growth Patterns: USMIRC Analysis.
Journal: Current oncology (Toronto, Ont.)
Published: May 05, 2026
Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis.
Journal: Transplantation and cellular therapy
Published: April 23, 2026
Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC.
Journal: Current oncology (Toronto, Ont.)
Published: March 17, 2026
Long-Term Gynecologic and Reproductive Health in Female Survivors of Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis of Prevalence.
Journal: Transplantation and cellular therapy
Published: March 14, 2026
High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis.
Journal: Current oncology (Toronto, Ont.)
Published: March 11, 2026
A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC Group.
Journal: Cancers
Published: December 12, 2025
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals.
Journal: Cancers
Published: September 19, 2025
Presence of Clonal Hematopoiesis and Cardiac Events After Allogeneic Stem Cell Transplantation.
Journal: Journal of the American Heart Association
Published: September 19, 2025
BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma and Renal Impairment.
Journal: Current oncology (Toronto, Ont.)
Published: September 15, 2025
Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 06, 2025
Last Updated: 09/26/2026